Compare Garmin Ltd. (GRMN) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Garmin Ltd. vs Inovio Pharmaceuticals Inc — how do they compare? Garmin Ltd. trades at $250.08 (market cap $46.62B), while Inovio Pharmaceuticals Inc trades at $1.14 (market cap $96.26M). The key difference: Garmin Ltd. is far larger — about 484.3× Inovio Pharmaceuticals Inc's market cap, and Garmin Ltd. pays a 1.74% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| GRMN | INO | |
|---|---|---|
Market Cap | $46.62B | $96.26M |
Sector | Technology | Health |
52-Week High | $267.52 | $2.87 |
52-Week Low | $187.10 | $1.05 |
Enterprise Value | $44.09B | $67.27M |
Dividend Yield | 1.74% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Garmin (GRMN) trades at $247.96, up 2.72% on the day, with a neutral technical outlook and mixed earnings history including recent beats. Revenue growth is strong, reaching $7.25B in 2025, with robust profitability margins. Recent news highlights product innovations in aviation and marine electronics, supporting growth prospects. The stock is near its consensus price target of $281.50, indicating moderate upside potential from current levels.
The outlook for GRMN is cautiously optimistic, driven by solid fundamentals and innovation, but tempered by high valuation ratios and a majority hold rating from analysts. Key risks include competitive pressures and market volatility, while institutional sentiment remains mixed with limited insider activity noted.
INO trades at $1.14, down 1.72% today, with a bearish technical signal from moving averages. The company shows minimal revenue of $65,340 in 2025 but has consistently beaten EPS estimates recently. Cash flow remains negative, though operating expenses are declining. A key FDA decision on INO-3107 is expected by October 30, 2026, representing a major catalyst.
The outlook hinges on regulatory approval for INO-3107. While analyst consensus is moderately bullish (53% buy ratings), significant financial losses and high valuation ratios pose substantial risks. The stock is a high-risk, event-driven investment dependent on successful drug commercialization to reverse its negative profitability trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Garmin Ltd.
Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.
Read more on GRMN →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
